Deciphex has secured a €15 million investment from Claret Capital Partners to enhance its AI-powered digital pathology services and aims for market leadership in the UK by 2027.
Information on the Target
Deciphex, a pioneer in AI-powered digital pathology, has secured a €15 million investment from Claret Capital Partners, recognized as Europe’s largest independent growth debt fund manager. This funding marks a significant step in Deciphex's strategy to enhance its provision of histopathology reporting services, aiming to become the market leader in the UK by 2027.
The investment will catalyze Deciphex's growth, particularly in the United States, while ensuring current shareholder value is preserved. The company’s dual-platform business model, featuring Diagnexia for clinical diagnostics and Patholytix for pharmaceutical research, is set to scale without additional shareholder dilution.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
In the UK, the healthcare landscape is currently strained, with more than 70% of medical decisions necessitating pathology examination. However, there is an increasing discrepancy between the risi
Similar Deals
Gilde Healthcare, Viking Global Investors → Mainstay Medical Holdings plc
2024
BGF → Avoca Clinic
2023
Unmind → Frankie Health
2023
Beechbrook Capital → Bio-Medical Research Limited
2019
BDO Development Capital Fund → Lifes2good Group
2015
BDO Development Capital Fund → Perigord
Claret Capital Partners
invested in
Deciphex
in 2025
in a Growth Equity & Expansion Capital deal
Disclosed details
Transaction Size: $15M